Sugi Predict

Sugi Predict / Compounds / SCHEMBL17155290

SCHEMBL17155290

SCHEMBL17155290

Cc1cc(-c2ccnc(C(F)F)c2)ncc1OC[C@@](C)(N)CC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 20/20 1.00
▸ MKNK1 Q9BUB5 6/20 0.81
▸ CIT O14578 5/20 0.81
▸ BMP2K Q9NSY1 5/20 0.81
▸ GAK O14976 4/20 0.81
▸ MYLK2 Q9H1R3 3/20 0.81
▸ SLC6A2 P23975 2/20 0.81
▸ KCNH2 Q12809 2/20 0.81
▸ MKNK2 Q9HBH9 2/20 0.81
▸ TNIK Q9UKE5 2/20 0.81
▸ CHRNA7 P36544 1/20 0.81
▸ LATS2 Q9NRM7 1/20 0.68
▸ ABCG2 Q9UNQ0 1/20 0.68
▸ PRKCB P05771 1/20 0.68
▸ AURKC Q9UQB9 1/20 0.68
▸ CYP3A4 P08684 3/20 0.67
▸ PRKG2 Q13237 2/20 0.67
▸ ROCK2 O75116 2/20 0.67
▸ PKN2 Q16513 1/20 0.67
▸ GSK3A P49840 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17143449 1.00 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL30061274 1.00 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL31338821 0.89 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL17155473 0.89 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL30059580 0.89 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL17143384 0.89 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL17144091 0.89 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL19901204 0.88 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL30059555 0.88 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK
SCHEMBL17143784 0.88 AAK1 (1.00) AAK1MKNK1CITBMP2KGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3126351-B1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-19 — — EP claimed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US claimed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US claimed
US-20250262197-A1 COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN LEXICON PHARMACEUTICALS, INC. (US) 2025-08-21 — — US disclosed
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 — — US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 — — US disclosed
WO-2023200892-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY LEXICON PHARMACEUTICALS, INC. (US) 2023-10-19 — — WO disclosed
US-20230330074-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY LEXICON PHARMACEUTICALS, INC. (US) 2023-10-19 — — US disclosed
US-11730723-B2 Compounds and methods for treating viral infections LEXICON PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-20210277001-A1 BIARYL KINASE INHIBITORS Cosmic Pet LLC 2021-09-09 — — US disclosed
US-20210277001-A1 BIARYL KINASE INHIBITORS Cosmic Pet LLC 2021-09-09 — — US disclosed
US-20180134704-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-17 — — US disclosed
US-20180134704-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-17 — — US disclosed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US disclosed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US disclosed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US disclosed
WO-2015153720-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134704-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885MKNK1 37/4885CIT 961/4885
US-20230330074-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY SMN1; SMN2, MUSK, GAB1 AAK1 62/4885MKNK1 545/4885CIT 2950/4885
US-20210277001-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885MKNK1 37/4885CIT 961/4885
US-20170183340-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885MKNK1 37/4885CIT 961/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS AAK1 1/4885MKNK1 37/4885CIT 961/4885
US-11730723-B2 Compounds and methods for treating viral infections EIF2AK2, SARS1, MAVS AAK1 147/4885MKNK1 909/4885CIT 4154/4885
US-20250262197-A1 COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN PNCK, CAMKK1, CAMK2G AAK1 33/4885MKNK1 194/4885CIT 955/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885MKNK1 37/4885CIT 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.